Skip to main content
Top
Published in: Diabetologia 2/2011

01-02-2011 | Article

Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort

Authors: A. M. Jacobson, C. M. Ryan, P. A. Cleary, B. H. Waberski, K. Weinger, G. Musen, W. Dahms, and the DCCT/EDIC Research Group

Published in: Diabetologia | Issue 2/2011

Login to get access

Abstract

Aims/hypothesis

In patients with type 1 diabetes, there has been concern about the effects of recurrent hypoglycaemia and chronic hyperglycaemia on cognitive function. Because other biomedical factors may also increase the risk of cognitive decline, this study examined whether macrovascular risk factors (hypertension, smoking, hypercholesterolaemia, obesity), sub-clinical macrovascular disease (carotid intima–media thickening, coronary calcification) and microvascular complications (retinopathy, nephropathy) were associated with decrements in cognitive function over an extended time period.

Methods

Type 1 diabetes patients (n = 1,144) who had completed a comprehensive cognitive test battery at entry into the Diabetes Control and Complications Trial were re-assessed at a mean of 18.5 (range: 15–23) years later. Univariate and multivariable models examined the relationship between cognitive change and the presence of micro- and macrovascular complications and risk factors.

Results

Univariate modelling showed that smoking history was modestly associated with decrements in learning, memory, spatial information-processing and psychomotor efficiency; hypertension was associated with only psychomotor slowing. Multivariable modelling demonstrated that HbA1c level, and retinal and renal complications were each independently associated with decrements in psychomotor efficiency. In contrast, no macrovascular risk factors were significant after correcting for multiple comparisons. No interactions were found between these predictors and sex, severe hypoglycaemic events or presence of the APOE ε4 allele.

Conclusions/interpretation

In relatively healthy, middle-aged adults with type 1 diabetes who had been followed for an average of 18.5 years, long-term metabolic control and microvascular factors are independently associated with a decline in cognitive function specifically affecting measures of psychomotor efficiency.

Trial registration

ClinicalTrials.gov NCT00360893

Funding

This study is supported by NIH grant number 5RO1 DK062218-02. The DCCT/EDIC project is supported by contracts with the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the General Clinical Research Centers Program, the Clinical and Translational Science Awards Program, the National Center for Research Resources and by Genentech through a Cooperative Research and Development Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brands AMA, Biessels G-J, de Haan EHF, Kappelle LJ, Kessels RPC (2005) The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diab Care 28:726–735CrossRef Brands AMA, Biessels G-J, de Haan EHF, Kappelle LJ, Kessels RPC (2005) The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diab Care 28:726–735CrossRef
2.
go back to reference Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Jacobson AM, Musen G et al (2007) Long-term effects of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRefPubMed Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Jacobson AM, Musen G et al (2007) Long-term effects of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRefPubMed
3.
go back to reference Brands AMA, Kessels RPC, Biessels GJ et al (2006) Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 55:1800–1806CrossRefPubMed Brands AMA, Kessels RPC, Biessels GJ et al (2006) Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 55:1800–1806CrossRefPubMed
4.
go back to reference Ferguson SC, Blane A, Perros P et al (2003) Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 52:149–156CrossRefPubMed Ferguson SC, Blane A, Perros P et al (2003) Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 52:149–156CrossRefPubMed
5.
go back to reference Wessels AM, Scheltens P, Barkhof F, Heine RJ (2008) Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol 585:88–96CrossRefPubMed Wessels AM, Scheltens P, Barkhof F, Heine RJ (2008) Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol 585:88–96CrossRefPubMed
6.
go back to reference Ryan CM, Geckle MO, Orchard TJ (2003) Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia 46:940–948CrossRefPubMed Ryan CM, Geckle MO, Orchard TJ (2003) Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia 46:940–948CrossRefPubMed
7.
go back to reference Brismar T, Maurex L, Cooray G et al (2007) Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology 32:1041–1051CrossRefPubMed Brismar T, Maurex L, Cooray G et al (2007) Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology 32:1041–1051CrossRefPubMed
8.
go back to reference Ryan CM, Williams TM, Orchard TJ, Finegold DN (1992) Psychomotor slowing is associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. Diabetes 41:107–113CrossRefPubMed Ryan CM, Williams TM, Orchard TJ, Finegold DN (1992) Psychomotor slowing is associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. Diabetes 41:107–113CrossRefPubMed
9.
go back to reference Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7:184–190CrossRefPubMed Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7:184–190CrossRefPubMed
10.
go back to reference Swan GE, Lessov-Schlaggar CN (2007) The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev 17:259–273CrossRefPubMed Swan GE, Lessov-Schlaggar CN (2007) The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev 17:259–273CrossRefPubMed
11.
go back to reference Obisesan TO, Obisesan OA, Martins S et al (2008) High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: The Third National Health and Nutrition Examination. J Am Geriatr Soc 56:501–509CrossRefPubMed Obisesan TO, Obisesan OA, Martins S et al (2008) High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: The Third National Health and Nutrition Examination. J Am Geriatr Soc 56:501–509CrossRefPubMed
12.
go back to reference Solomon A, Käreholt I, Ngandu T et al (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one year follow-up study. Neurology 68:751–756CrossRefPubMed Solomon A, Käreholt I, Ngandu T et al (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one year follow-up study. Neurology 68:751–756CrossRefPubMed
13.
go back to reference Muller M, Grobbee DE, Aleman A, Bots M, van der Schouw YT (2007) Cardiovascular disease and cognitive performance in middle-aged and elderly men. Atherosclerosis 190:140–149CrossRef Muller M, Grobbee DE, Aleman A, Bots M, van der Schouw YT (2007) Cardiovascular disease and cognitive performance in middle-aged and elderly men. Atherosclerosis 190:140–149CrossRef
14.
go back to reference Romero JR, Beiser A, Seshadri S et al (2009) Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: The Framingham Study. Stroke 40:1590–1596CrossRefPubMed Romero JR, Beiser A, Seshadri S et al (2009) Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: The Framingham Study. Stroke 40:1590–1596CrossRefPubMed
15.
go back to reference Manschot SM, Biessels GJ, de Valk HW et al (2007) Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 50:2388–2397CrossRefPubMed Manschot SM, Biessels GJ, de Valk HW et al (2007) Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 50:2388–2397CrossRefPubMed
16.
go back to reference Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
17.
go back to reference Diabetes Control and Complications Trial Research Group (1996) Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 124:379–388 Diabetes Control and Complications Trial Research Group (1996) Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 124:379–388
18.
go back to reference Wechsler D (1955) Manual for the Wechsler adult intelligence scale. Psychological Corporation, New York Wechsler D (1955) Manual for the Wechsler adult intelligence scale. Psychological Corporation, New York
19.
go back to reference Reitan RM, Wolfson D (1993) The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Neuropsychology Press, Tucson Reitan RM, Wolfson D (1993) The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Neuropsychology Press, Tucson
20.
go back to reference Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 19:87–95CrossRef Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 19:87–95CrossRef
21.
go back to reference Lewis RF (1990) Digit vigilance test. Psychological Assessment Resources, Lutz Lewis RF (1990) Digit vigilance test. Psychological Assessment Resources, Lutz
22.
go back to reference Ruff RM, Parker SB (1993) Gender- and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the finger tapping and grooved pegboard tests. Percept Mot Skills 76:1219–1230PubMed Ruff RM, Parker SB (1993) Gender- and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the finger tapping and grooved pegboard tests. Percept Mot Skills 76:1219–1230PubMed
23.
go back to reference Mitrushina MN, Boone KB, D'Elia LF (1999) Handbook of normative data for neuropsychological assessment. Oxford University Press, New York Mitrushina MN, Boone KB, D'Elia LF (1999) Handbook of normative data for neuropsychological assessment. Oxford University Press, New York
24.
go back to reference Morrow LA, Ryan CM (2002) Normative data for a working memory test: the four word short-term memory test. Clin Neuropsychol 16:373–380PubMed Morrow LA, Ryan CM (2002) Normative data for a working memory test: the four word short-term memory test. Clin Neuropsychol 16:373–380PubMed
25.
go back to reference Ryan CM, Morrow LA, Bromet EJ, Parkinson DK (1987) Assessment of neuropsychological dysfunction in the workplace: normative data from the Pittsburgh Occupational Exposures Test Battery. J Clin Exp Neuropsychol 9:665–679CrossRefPubMed Ryan CM, Morrow LA, Bromet EJ, Parkinson DK (1987) Assessment of neuropsychological dysfunction in the workplace: normative data from the Pittsburgh Occupational Exposures Test Battery. J Clin Exp Neuropsychol 9:665–679CrossRefPubMed
26.
go back to reference Lezak MD (1995) Neuropsychological assessment. Oxford University Press, New York Lezak MD (1995) Neuropsychological assessment. Oxford University Press, New York
27.
go back to reference Epidemiology of Diabetes Interventions and Complications(EDIC) (1999) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diab Care 22:99–111CrossRef Epidemiology of Diabetes Interventions and Complications(EDIC) (1999) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diab Care 22:99–111CrossRef
28.
go back to reference Steffes M, Cleary P, Goldstein D et al (2005) Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 51:753–758CrossRefPubMed Steffes M, Cleary P, Goldstein D et al (2005) Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 51:753–758CrossRefPubMed
29.
go back to reference Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271–286CrossRef Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271–286CrossRef
30.
go back to reference Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381–389CrossRef Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381–389CrossRef
31.
go back to reference Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348:2294–2303CrossRef Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2003) Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348:2294–2303CrossRef
32.
go back to reference Cleary PA, Orchard TJ, Genuth S et al (2006) The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 55:3556–3565CrossRefPubMed Cleary PA, Orchard TJ, Genuth S et al (2006) The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 55:3556–3565CrossRefPubMed
33.
go back to reference Murdoch SJ, Boright AP, Paterson AD et al (2007) LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes. Atherosclerosis 192:138–147CrossRefPubMed Murdoch SJ, Boright AP, Paterson AD et al (2007) LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes. Atherosclerosis 192:138–147CrossRefPubMed
34.
go back to reference Yoav B, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Stat Methodol 57:125–133 Yoav B, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Stat Methodol 57:125–133
35.
go back to reference Ryan CM (2005) Diabetes, aging, and cognitive decline. Neurobiol Aging 26S:S21–S25CrossRef Ryan CM (2005) Diabetes, aging, and cognitive decline. Neurobiol Aging 26S:S21–S25CrossRef
36.
go back to reference Wong TY, Klein R, Sharrett AR et al (2002) Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 33:1487–1492CrossRefPubMed Wong TY, Klein R, Sharrett AR et al (2002) Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 33:1487–1492CrossRefPubMed
37.
go back to reference Wong TY, Mosley TH, Klein R et al (2003) Retinal microvascular changes and MRI signs of cerebral atrophy in healthy, middle-aged people. Neurology 61:806–811PubMed Wong TY, Mosley TH, Klein R et al (2003) Retinal microvascular changes and MRI signs of cerebral atrophy in healthy, middle-aged people. Neurology 61:806–811PubMed
38.
go back to reference Cooper LS, Wong TY, Klein R et al (2006) Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. Stroke 37:82–86CrossRefPubMed Cooper LS, Wong TY, Klein R et al (2006) Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. Stroke 37:82–86CrossRefPubMed
39.
go back to reference Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat 206:319–348CrossRefPubMed Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat 206:319–348CrossRefPubMed
40.
go back to reference Wong TY, Klein R, Klein BEK, Tielsch JM, Hubbard L, Nieto FJ (2001) Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 46:59–80CrossRefPubMed Wong TY, Klein R, Klein BEK, Tielsch JM, Hubbard L, Nieto FJ (2001) Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 46:59–80CrossRefPubMed
41.
go back to reference Qiu C, Cotch MF, Sigurdsson S et al (2008) Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility-Reykjavik Study. Diabetes 57:1645–1650CrossRefPubMed Qiu C, Cotch MF, Sigurdsson S et al (2008) Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility-Reykjavik Study. Diabetes 57:1645–1650CrossRefPubMed
42.
go back to reference Lyoo IK, Yoon SJ, Musen G et al (2009) Altered prefrontal glutamate-glutamine-γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. Arch Gen Psychiatry 66:879–887CrossRef Lyoo IK, Yoon SJ, Musen G et al (2009) Altered prefrontal glutamate-glutamine-γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. Arch Gen Psychiatry 66:879–887CrossRef
43.
go back to reference Heikkilä O, Lundbom N, Timonen M, Groop P-H, Heikkinen S, Mäkimattila S (2009) Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia 52:534–540CrossRefPubMed Heikkilä O, Lundbom N, Timonen M, Groop P-H, Heikkinen S, Mäkimattila S (2009) Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia 52:534–540CrossRefPubMed
44.
go back to reference Northam EA, Rankins D, Lin A et al (2009) Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diab Care 32:445–450CrossRef Northam EA, Rankins D, Lin A et al (2009) Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diab Care 32:445–450CrossRef
46.
go back to reference Kodl CT, Franc DT, Rao JP et al (2008) Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes 57:3083–3089CrossRefPubMed Kodl CT, Franc DT, Rao JP et al (2008) Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes 57:3083–3089CrossRefPubMed
47.
go back to reference Gläscher J, Tranel D, Paul LK et al (2009) Lesion mapping of cognitive abilities linked to intelligence. Neuron 61:681–691CrossRefPubMed Gläscher J, Tranel D, Paul LK et al (2009) Lesion mapping of cognitive abilities linked to intelligence. Neuron 61:681–691CrossRefPubMed
48.
go back to reference Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48:2460–2469CrossRefPubMed Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48:2460–2469CrossRefPubMed
49.
go back to reference Hassing LB, Hofer SM, Nilsson SE et al (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33:355–361CrossRefPubMed Hassing LB, Hofer SM, Nilsson SE et al (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33:355–361CrossRefPubMed
50.
go back to reference Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR (2009) Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 40:3180–3185CrossRefPubMed Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR (2009) Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 40:3180–3185CrossRefPubMed
Metadata
Title
Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort
Authors
A. M. Jacobson
C. M. Ryan
P. A. Cleary
B. H. Waberski
K. Weinger
G. Musen
W. Dahms
and the DCCT/EDIC Research Group
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1883-9

Other articles of this Issue 2/2011

Diabetologia 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.